The liposomal amphotericin B (AmB) formulation, AmBisome®, still represents the best therapeutic option for cutaneous and visceral leishmaniasis. However, its clinical efficacy depends on the patient’s immunological status, the clinical manifestation and the endemic region. Moreover, the need for parenteral administration, its side effects and high cost significantly limit its use in developing countries. This review reports the progress achieved thus far toward the understanding of the mechanism responsible for the reduced toxicity of liposomal AmB formulations and the factors that influence their efficacy against leishmaniasis. It also presents the recent advances in the development of more effective liposomal AmB formulations, including topical and oral liposome formulations. The critical role of the AmB aggregation state and release rate in the reduction of drug toxicity and in the drug efficacy by non-invasive routes is emphasized. This paper is expected to guide future research and development of innovative liposomal formulations of AmB.
Aim: Amphotericin B (AmB) is an antileishmanial drug with high toxicity; however, this drawback might overcome by decreasing the AmB self-aggregation state. This work aimed at evaluating the influe... Graphical abstract
Leishmaniasis is a neglected tropical disease that mainly affects socially vulnerable populations. It is caused by various Leishmania species, and manifests primarily as cutaneous (CL) or visceral leishmaniasis (VL). AmBisome, a commercial formulation of amphotericin B (AmB) with conventional liposomes, is the most effective for VL treatment, but its efficacy is limited in some CL cases and immunocompromised patients. This work evaluated a new PEGylated liposomal formulation (LAmB-RA) coencapsulating AmB and retinoic acid (RA), as an immunomodulator, for CL treatment. LAmB-RA displayed a mean size of 125 nm, a polydispersity index <0.2, and high encapsulation efficiencies for AmB (97.1%) and RA (94.7%). Although SAXS analysis indicates that RA did not induce major structural rearrangements in the liposomal bilayer, comparison of circular dichroism spectra between LAmB-RA and the liposomal AmB formulation without RA (LAmB) revealed slightly different aggregated states of AmB. In addition, LAmB-RA showed a significantly reduced hemolytic activity, compared to LAmB. Pharmacokinetic analysis of the PEGylated formulations showed higher Cmax and prolonged plasma exposure of AmB compared to AmBisome. In Leishmania major-infected mice, LAmB-RA significantly reduced lesion size and parasite burden (99%) versus untreated control. In the Leishmania amazonensis model, it markedly inhibited lesion progression and was the only treatment to significantly reduce parasite load in the spleen (by 60%). Additionally, LAmB-RA promoted an increase in the IFN-γ/IL-10 ratio in antigen-stimulated splenocytes compared to LAmB, indicating a Th1-skewed immune response. These results support LAmB-RA as a promising therapeutic strategy for CL, combining prolonged circulation and enhanced efficacy.
Aim: To develop nanoemulsions (NEs) loading amphotericin B (AmB) and to evaluate the influence of different excipients on the stability and the supramolecular organization, retention and toxicity o... Graphical abstract Disteaoryl phosphatidylglycerol and dioleoyl phosphatidylglycerol form a hydrophobic ion pair with amphotericin B in nanoemulsions, enhancing drug retention after dispersion and ...